Page last updated: 2024-08-25

almagate and Proliferative Vitreoretinopathy

almagate has been researched along with Proliferative Vitreoretinopathy in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Buil-Calvo, JA; Cordero, JA; Evans, JR; Martí-Carvajal, AJ; Martinez-Zapata, MJ; Pijoán, JI; Solà, I1
Abdallah, W; Fawzi, AA1

Reviews

2 review(s) available for almagate and Proliferative Vitreoretinopathy

ArticleYear
Anti-vascular endothelial growth factor for proliferative diabetic retinopathy.
    The Cochrane database of systematic reviews, 2014, Nov-24, Issue:11

    Topics: Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Female; Humans; Light Coagulation; Male; Randomized Controlled Trials as Topic; Ranibizumab; Vascular Endothelial Growth Factor A; Visual Acuity; Vitrectomy; Vitreoretinopathy, Proliferative

2014
Anti-VEGF therapy in proliferative diabetic retinopathy.
    International ophthalmology clinics, 2009,Spring, Volume: 49, Issue:2

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Disease Models, Animal; Humans; Injections; Ranibizumab; Treatment Outcome; Vascular Endothelial Growth Factor A; Vitreoretinopathy, Proliferative; Vitreous Body

2009